Ratios

		vs industry	vs history
P/B	4.34	MNOV's P/B is ranked higher than 79% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 3.80 vs. MNOV: 4.34 )	MNOV' s 10-Year P/B Range Min: 0.15   Max: 4.51 Current: 4.34 0.15 4.51
P/S	88.50	MNOV's P/S is ranked lower than 78% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 6.90 vs. MNOV: 88.50 )	MNOV' s 10-Year P/S Range Min: 32.2   Max: 472.67 Current: 88.5 32.2 472.67
EV-to-EBIT	-6.71	MNOV's EV-to-EBIT is ranked higher than 88% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 14.61 vs. MNOV: -6.71 )	MNOV' s 10-Year EV-to-EBIT Range Min: 0   Max: 0 Current: -6.71

Valuation & Return

		vs industry	vs history
Price/Tangible Book	130.4	MNOV's Price/Tangible Book is ranked higher than 89% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 4.70 vs. MNOV: 130.4 )	MNOV' s 10-Year Price/Tangible Book Range Min: 1.4   Max: 54.7 Current: 130.4 1.4 54.7
Price/Median PS Value	0.5	MNOV's Price/Median PS Value is ranked lower than 52% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 0.90 vs. MNOV: 0.5 )	MNOV' s 10-Year Price/Median PS Value Range Min: 0.2   Max: 3.5 Current: 0.5 0.2 3.5

Business Description

Medicinova, Inc. was incorporated in Delaware in September 2000. It is a biopharmaceutical company focused on acquiring and developing novel, small molecule therapeutics for the treatment of diseases with unmet medical need with a specific focus on the U.S. market. Through strategic alliances mainly with Japanese pharmaceutical companies, Medicinova is developing six clinical-stage compounds for the treatment of asthma, chronic obstructive pulmonary disease exacerbations of asthma, multiple sclerosis, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder/insomnia, preterm labor and urinary incontinence. Additionally, the company is focuses on two product candidates for the treatment of thrombotic disorders, MN-221 for the treatment of acute exacerbation of asthma and MN-166 for the treatment of multiple sclerosis. Medicinova's other product development programs consist of: MN-001 for the treatment of bronchial asthma. MN-001 for the treatment of interstitial cystitis, MN-029 for the treatment of solid tumors, MN-305 for the treatment of Generalized Anxiety Disorder/insomnia, MN-221 for the treatment of preterm labor, MN-246 for the treatment of urinary incontinence, MN-447 for the treatment of thrombotic disorders and MN-462 for the treatment of thrombotic disorders. The company use external service providers to manufacture its product candidates to be used in clinical trials and for the majority of the services performed in connection with the preclinical and clinical development of its product candidates. Government authorities in the United States and other countries extensively regulate the research, development, testing, manufacture, labeling, promotion, advertising, distribution, sampling, marketing, and import and export of pharmaceutical products and biologics such as those it is developing.
Company Website
SEC Reports

Industry:	Biotechnology
Compare:	NONOF, AMGN, GILD, BIIB, CELG
Traded in other countries:	4875.Japan

» More Articles for MNOV

Headlines

Articles On GuruFocus.com

Personalized Checklist